Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
about
Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.The management of refractory carcinoid syndrome: challenges and opportunities ahead.Carcinoid-syndrome: recent advances, current status and controversies.
P2860
Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Long-term outcome and toxicity ...... d metastatic carcinoid tumors.
@ast
Long-term outcome and toxicity ...... d metastatic carcinoid tumors.
@en
type
label
Long-term outcome and toxicity ...... d metastatic carcinoid tumors.
@ast
Long-term outcome and toxicity ...... d metastatic carcinoid tumors.
@en
prefLabel
Long-term outcome and toxicity ...... d metastatic carcinoid tumors.
@ast
Long-term outcome and toxicity ...... d metastatic carcinoid tumors.
@en
P2093
P1476
Long-term outcome and toxicity ...... d metastatic carcinoid tumors.
@en
P2093
Amir Sabet
Charlotte J Yong-Hing
Frank Grünwald
Hans-Jürgen Biersack
Khaled Alkawaldeh
Samer Ezziddin
Timur Logvinski
P304
P356
10.2967/JNUMED.112.119313
P407
P577
2013-10-07T00:00:00Z